Mankind Pharma Signs Licensing Pact with Innovent for Sintilimab

    Listen to our Podcast: Grow your wealth and keep it secure.

    0:00 / 0:00

    Synopsis:

    Mankind Pharma signed a licensing deal with Innovent Biologics to introduce Sintilimab, an anti-cancer PD-1 immunotherapy, in India. Estimated market size is ₹8,000 crore. Mankind Pharma share price remains stable amid this expansion into oncology.

    Mankind Pharma news today

    Mankind Pharma has announced a licensing agreement with Chinese pharmaceutical giant Innovent Biologics to introduce Sintilimab, a cutting-edge PD-1 immunotherapy, in India. The partnership grants Mankind exclusive rights to register, import, market, sell, and distribute the drug, while Innovent oversees manufacturing and supply. This development signifies Mankind’s strategic focus on strengthening its oncology portfolio in the ₹8,000-crore Indian oncology market.

    Also read: Jubilant FoodWorks Partners with Coca-Cola for Beverage Supply

    Mankind Pharma Limited

    Trade

    2599.8-25.19 (-0.95 %)

    Updated - 19 November 2026
    2632.70day high
    DAY HIGH
    2584.00day low
    DAY LOW
    341887
    VOLUME (BSE)

    Key Takeaways

    • Drug Name: Sintilimab (Marketed as TYVYT in China).

    • Mechanism: Blocks PD-1/PD-L1 pathway to enhance T-cell activity against cancer cells.

    • Launch Timeline: Expected in three years post Phase III trials and regulatory approvals.

    • Market Size: Indian oncology market valued at ₹8,000 crore.

    • Mankind Pharma Share Price: Stable amid announcement.

    Also read: IndusInd Bank to Sell ₹1,573-Crore MFI Retail Loan Pool in Auction

    Sintilimab Overview

    Sintilimab, developed by Innovent Biologics in collaboration with Eli Lilly, is a monoclonal antibody targeting multiple cancer types. It is approved for eight indications in China, including:

    Cancer Type

    Indications

    Non-Small Cell Lung Cancer

    First-Line Treatment

    Liver Cancer

    Advanced Stages

    Gastric Cancer

    First-Line Therapy

    Esophageal Cancer

    Recurrence or Advanced Cases

    Endometrial Cancer

    Advanced Stages

    Hodgkin’s Lymphoma

    Second-Line Therapy

    Strategic Importance for Mankind Pharma

    Mankind’s entry into oncology began in 2023 with the acquisition of Panacea Biotec for ₹1,872 crore. The addition of Sintilimab aligns with the company's focus on biologics and immunotherapies as future cancer treatments. The drug's competitive pricing is expected to enhance accessibility in the Indian market.

    Mankind Pharma Share Price and Market Impact

    Mankind Pharma share price remains steady following the announcement, reflecting investor confidence in its strategic expansion. With over 16,000 personnel and 13,000 stockists, Mankind’s robust distribution network is well-positioned to support the launch. 

    Mankind Pharma’s licensing agreement with Innovent Biologics marks a significant step towards transforming cancer care in India. By introducing Sintilimab, the company is poised to make advanced immunotherapy accessible to Indian patients while solidifying its position in the oncology market.

    Also read: Gensol Engineering Secures ₹897-Crore Contract for NTPC REL Solar Projects

    Do you have a trading account app or demat account app?

    You can open an account with Bajaj Broking in minutes.

    Download the Bajaj Broking app now from Play Store or App Store.

    Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

    This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

    Share this article: 

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Publish Date: 27 Dec 2024

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    Scan the QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹8,422 Cr+ MTF Book

    Open Your Free Demat Account

    Access Research Backed Stock Recommendations

    +91

    |

    Open Your Free Demat Account

    Access Research Backed Stock Recommendations

    +91

    |